OpenBit ResearchOpenBit
中文

What's driving Incyte (INCY)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Atebrioz Treatment Trajectory in FOP

Why it matters now

Atebrioz approval can affect INCY revenue through treatment availability in the approved FOP population; the supplied corpus does not quantify the resulting exposure.

Next checkpoint

INCY earnings (expected 2026-10-27)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to INCY, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

Subsequent official evidence materially removes or limits the approval, shows that Atebrioz is not used in the approved population, or contradicts the reported treatment trajectory.

Research drivers

  • Atebrioz Treatment Trajectory in FOP

    Bullish · Active · Updated

    Atebrioz has obtained FDA approval for FOP in adults and pediatric patients aged 12 years and older.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • Atebrioz functions as an activin receptor-like kinase 2 inhibitor.

    Relayed by: Benzinga · Event date on record:

  • The European Medicines Agency is reviewing a marketing authorization application for zilurgisertib for patients aged 12 and older.

    Relayed by: Benzinga · Event date on record:

  • The PROGRESS study completed enrollment of children aged six to under 12 in Cohort 2 and is actively enrolling children aged two to under 12 in Cohort 3.

    Relayed by: Benzinga · Event date on record:

  • In Cohort 1 of the PROGRESS clinical study, patients taking zilurgisertib had a mean decrease of 3.2 cubic centimeters in total new heterotopic ossification lesion volume over the 24-week double-blind period, while placebo recipie

    Relayed by: Benzinga · Event date on record:

  • The treatment effects of zilurgisertib continued through the 48-week open-label extension.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.